GLP-1

Market Access

Boehringer US head talks GLP-1s, PBMs, Trump at Reuters USA

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.

Market Access

UK weight loss market: M&A opportunities

Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Small study finds GLP-1 drug can curb excess alcohol use

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

Digital

Looking beyond the scale: Why measures of physical activity ...

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

R&D

Clinical trends for 2025: A year of change

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.